{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Age-related+Macular+Degeneration+%28AMD%29&page=28",
    "query": {
      "condition": "Age-related Macular Degeneration (AMD)",
      "page": 28
    },
    "page_size": 10
  },
  "pagination": {
    "page": 28,
    "page_size": 10,
    "total_count": 908,
    "total_pages": 91,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Age-related+Macular+Degeneration+%28AMD%29&page=29&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Age-related+Macular+Degeneration+%28AMD%29&page=27&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-15T23:52:48.287Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02348359",
      "title": "X-82 to Treat Age-related Macular Degeneration",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Age-Related Macular Degeneration (AMD)",
        "Macular Degeneration",
        "Exudative Age-related Macular Degeneration",
        "AMD",
        "Macular Degeneration, Age-related, 10",
        "Eye Diseases",
        "Retinal Degeneration",
        "Retinal Diseases"
      ],
      "interventions": [
        {
          "name": "X-82",
          "type": "DRUG"
        },
        {
          "name": "Anti-VEGF",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tyrogenex",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 157,
      "start_date": "2015-03-16",
      "completion_date": "2018-01-12",
      "has_results": true,
      "last_update_posted_date": "2022-02-11",
      "last_synced_at": "2026-10-15T23:52:48.287Z",
      "location_count": 35,
      "location_summary": "Tucson, Arizona • Beverly Hills, California • Huntington Beach, California + 32 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Redlands",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02348359"
    },
    {
      "nct_id": "NCT05643118",
      "title": "Evaluation of OLX10212 in Patients With Neovascular Age-related Macular Degeneration",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neovascular Age-related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "OLX10212 is a cell penetrating asymmetric small interference RNA (cp-asiRNA)",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "Olix Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2023-01-04",
      "completion_date": "2025-11-10",
      "has_results": false,
      "last_update_posted_date": "2025-12-11",
      "last_synced_at": "2026-10-15T23:52:48.287Z",
      "location_count": 5,
      "location_summary": "Santa Maria, California • Oak Forest, Illinois • St Louis, Missouri + 2 more",
      "locations": [
        {
          "city": "Santa Maria",
          "state": "California"
        },
        {
          "city": "Oak Forest",
          "state": "Illinois"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Troy",
          "state": "New York"
        },
        {
          "city": "Bellaire",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05643118"
    },
    {
      "nct_id": "NCT00464581",
      "title": "Lucentis for Treatment of Macular Edema",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Cystoid Macular Edema"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Retina Institute of Hawaii",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "Up to 90 Years"
      },
      "enrollment_count": 30,
      "start_date": "2007-05",
      "completion_date": "2009-12",
      "has_results": false,
      "last_update_posted_date": "2012-05-28",
      "last_synced_at": "2026-10-15T23:52:48.287Z",
      "location_count": 1,
      "location_summary": "Honolulu, Hawaii",
      "locations": [
        {
          "city": "Honolulu",
          "state": "Hawaii"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00464581"
    },
    {
      "nct_id": "NCT01581411",
      "title": "Intra-arterial Thrombolysis for Severe Recent Central Retinal Vein Occlusion",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Central Retinal Vein Occlusion"
      ],
      "interventions": [
        {
          "name": "Tissue Plasminogen Activator",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Weill Medical College of Cornell University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 1,
      "start_date": "2012-01",
      "completion_date": "2015-11",
      "has_results": false,
      "last_update_posted_date": "2018-08-06",
      "last_synced_at": "2026-10-15T23:52:48.287Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01581411"
    },
    {
      "nct_id": "NCT02214628",
      "title": "Phase 2A Open Label Safety Study of Fovista® (Anti-PDGF BB) Regimen Administered in Combination With Anti-VEGF Therapy to Study Sub-Retinal Fibrosis in Neovascular AMD",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Age-related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "Fovista® (anti-PDGF BB) plus anti-VEGF",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ophthotech Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 101,
      "start_date": "2014-07",
      "completion_date": "2016-12",
      "has_results": true,
      "last_update_posted_date": "2024-02-23",
      "last_synced_at": "2026-10-15T23:52:48.287Z",
      "location_count": 13,
      "location_summary": "Phoenix, Arizona • Beverly Hills, California • Sacramento, California + 9 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Santa Ana",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02214628"
    },
    {
      "nct_id": "NCT02061865",
      "title": "Phase 1 Safety Study With Intravitreal (IVT) REGN2176-3 in Patients Aged 50 Years and Older With Wet AMD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neovascular Wet Age-related Macular Degeneration (AMD)"
      ],
      "interventions": [
        {
          "name": "REGN2176-3",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2014-02",
      "completion_date": "2014-12",
      "has_results": false,
      "last_update_posted_date": "2015-02-11",
      "last_synced_at": "2026-10-15T23:52:48.287Z",
      "location_count": 4,
      "location_summary": "Beverly Hills, California • Colorado Springs, Colorado • Boston, Massachusetts + 1 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02061865"
    },
    {
      "nct_id": "NCT02402660",
      "title": "Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Stargardt Disease",
        "Stargardt Macular Degeneration",
        "Stargardt Macular Dystrophy",
        "Autosomal Recessive Stargardt Disease 1 (ABCA4-related)"
      ],
      "interventions": [
        {
          "name": "ALK-001",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alkeus Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "8 Years to 70 Years"
      },
      "enrollment_count": 160,
      "start_date": "2015-08",
      "completion_date": "2028-11-30",
      "has_results": false,
      "last_update_posted_date": "2026-09-21",
      "last_synced_at": "2026-10-15T23:52:48.287Z",
      "location_count": 14,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 11 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02402660"
    },
    {
      "nct_id": "NCT03972709",
      "title": "A Study Assessing the Safety, Tolerability, and Efficacy of Galegenimab (FHTR2163) in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Macular Degeneration, Age-Related",
        "Geographic Atrophy"
      ],
      "interventions": [
        {
          "name": "Galegenimab",
          "type": "DRUG"
        },
        {
          "name": "Sham Control",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genentech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "60 Years and older"
      },
      "enrollment_count": 372,
      "start_date": "2019-06-03",
      "completion_date": "2022-10-27",
      "has_results": true,
      "last_update_posted_date": "2024-03-27",
      "last_synced_at": "2026-10-15T23:52:48.287Z",
      "location_count": 72,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Bakersfield, California + 65 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Encino",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03972709"
    },
    {
      "nct_id": "NCT03386474",
      "title": "Study of Safety and Efficacy of Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With nAMD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Neovascular Age-related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "Brolucizumab 6 mg",
          "type": "DRUG"
        },
        {
          "name": "Aflibercept 2 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 151,
      "start_date": "2018-01-15",
      "completion_date": "2018-09-06",
      "has_results": true,
      "last_update_posted_date": "2021-01-05",
      "last_synced_at": "2026-10-15T23:52:48.287Z",
      "location_count": 63,
      "location_summary": "Peoria, Arizona • Phoenix, Arizona • Arcadia, California + 56 more",
      "locations": [
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Arcadia",
          "state": "California"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03386474"
    },
    {
      "nct_id": "NCT02126423",
      "title": "Resistance to Antibiotics in Patients Receiving Eye Injections",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Age-Related Macular Degeneration",
        "Retinal Vein Occlusion",
        "Diabetic Retinopathy"
      ],
      "interventions": [
        {
          "name": "Conjunctival and nasopharyngeal swabs",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Prism Vision Group",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2014-05",
      "completion_date": "2014-09",
      "has_results": false,
      "last_update_posted_date": "2016-06-01",
      "last_synced_at": "2026-10-15T23:52:48.287Z",
      "location_count": 1,
      "location_summary": "Edison, New Jersey",
      "locations": [
        {
          "city": "Edison",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02126423"
    }
  ]
}